ANACOR'S AN0128 LOOKS PROMISING IN ATOPIC DERMATITIS

Anacor Pharmaceuticals has reported positive data from Phase I clinical and preclinical studies of AN0128, the company's novel topical compound currently in Phase II clinical trials for atopic dermatitis. These studies demonstrated that AN0128 was well tolerated at the site of application and indicated that further study was warranted.

Anacor is currently enrolling patients in a double-blind, placebo-controlled Phase II study of AN0128 for the treatment of atopic dermatitis. The study will evaluate 100 patients at multiple U.S. centers.